Search
Researchers have clarified the process by which developing nerve cells are directed to specialize into distinct parts.
The findings could pave the way toward more targeted treatments for the disease.
Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments.
Memorial Sloan Kettering has convened a COVID-19 Operating Room Executive Committee to scrutinize all surgical cases and determine whether they were truly essential and to review needs, resources, and ICU availability.
An MSK medical oncologist and geneticist discusses the latest drug approved for breast cancer and how genetic testing can lead to new treatments.
Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013 to expedite early-stage drug discovery of innovative new therapies. Under this expansion, Tri-I TDI will extend its current relationship with its industry partner, Takeda Pharmaceutical Company, Ltd. from the realm of small molecule discovery into the new research area of antibody drug discovery. All three institutions will benefit from Tri-I TDI’s expansion.
Read about a CAR T cell therapy that appears effective against light chain (AL) amyloidosis.
The scientific world lost one of its greats this week. Here, we reflect on his influence.
In recognition of Breast Cancer Awareness Month, MSK shared four stories about new developments and advances in breast cancer prevention, research and treatment being conducted by MSK clinicians and researchers.
In an international study led by MSK, researchers reported finding key mutations driving the disease histiocytosis for nearly all of the people included.